HDV vs XBI
iShares Core High Dividend ETF vs SPDR S&P Biotech ETF
- • HDV has the lower expense ratio at 0.08% vs 0.35% for XBI.
- • HDV pays a higher dividend yield (2.88%).
Side-by-side metrics
| Metric | HDV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.08% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.88% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $13.57B | $8.30B |
YTD return | 12.20% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.37 | 1.09 |
P/E ratio | 21.90 | — |
Last price | $26.91 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
HDV top holdings
| XOM | Exxon Mobil Corp | 8.42% |
| CVX | Chevron Corp | 6.42% |
| JNJ | Johnson & Johnson | 5.68% |
| ABBV | AbbVie Inc | 5.44% |
| PG | Procter & Gamble Co | 4.46% |
| PM | Philip Morris International Inc | 4.17% |
| HD | The Home Depot Inc | 4.07% |
| KO | Coca-Cola Co | 3.86% |
| PGR | Progressive Corp | 3.79% |
| MRK | Merck & Co Inc | 3.77% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About HDV
HDV (iShares Core High Dividend ETF) is US high-dividend stocks with quality screen. Managed by iShares, the fund carries $13.6B in assets under management, an expense ratio of 0.08%, a dividend yield of 2.88%. Its largest holding is Exxon Mobil Corp (XOM), which represents 8.4% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 6.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.